All In Biotech

NDA 011265 · Ani Pharms

Promethazine Hydrochloride and Dextromethorphan Hydrobromide

Dextromethorphan Hydrobromide, Promethazine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Sep 16, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1957

Dec 3, 1957

Approved uses

3

Original approval plus efficacy supplements

Registered trials

206

29 Phase 3, 17 recruiting

FAERS reports

3

2 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution should not be used in pediatric patients less than 2 years of age because of the potential for fatal respiratory depression. Postmarketing cases of respiratory depression, including fatalities, have been reported with use of promethazine in pediatric patients less than 2 years of age. A wide range of weight-based doses of promethazine have resulted in respiratory depression in these patients. Caution should be exercised when administering promethazine to pediatric patients 2 years of age and older. It is recommended that the lowest effective dose of promethazine be used in pediatric patients 2 years of age and older and concomitant administration of other drugs with respiratory depressant effects be avoided.

What it is approved for

From the label in effect Aug 8, 2025.

INDICATIONS AND USAGE Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 11, 1988 Supplement 19 · Efficacy
  • Apr 2, 1984 Supplement 13 · Efficacy
  • Dec 3, 1957 Original approval · Type 4 - New Combination
1 products under this application
  • PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE · DEXTROMETHORPHAN HYDROBROMIDE 15MG/5ML; PROMETHAZINE HYDROCHLORIDE 6.25MG/5ML · SYRUP, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextromethorphan Hydrobromide" as an intervention, any sponsor and status, largest first.

All 206 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • colectomy1
  • intestinal obstruction1
  • neuropathy peripheral1
  • product use in unapproved indication1
  • somnolence1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20241
20251

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 28 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.